Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.16
- Piotroski Score 4.00
- Grade Buy
- Symbol (RGLS)
- Company Regulus Therapeutics Inc.
- Price $1.58
- Changes Percentage (-3.07%)
- Change -$0.05
- Day Low $1.58
- Day High $1.67
- Year High $3.79
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.45
- Trailing P/E Ratio -1.54
- Forward P/E Ratio -1.54
- P/E Growth -1.54
- Net Income $-30,037,000
Income Statement
Quarterly
Annual
Latest News of RGLS
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Regulus Therapeutics Inc.'s (NASDAQ:RGLS) high institutional ownership speaks for itself as stock continues to impress, up 11% over last week
Ownership data and analyst forecasts provide insight into a company's potential. Regulus Therapeutics Inc. has institutions as the major shareholders with significant gains for investors. Understandin...
By Yahoo! Finance | 3 months ago
